Epidermal growth factor secreted from submandibular salivary glands interferes with the lipolytic effect of adrenaline in mice.
We had described that epidermal growth factor (EGF) interfered with the lipolytic effect of catecholamines in isolated adipocytes. Since catecholamines stimulate the release of EGF from submandibular salivary glands to blood plasma in male mice, we studied whether EGF affected also the lipolytic response to adrenaline in whole animals. We studied the effect of adrenaline in sialoadenectomized and sham-operated mice receiving or not a high dose of EGF following adrenaline injection. There was no difference in plasma EGF concentration between sham-operated and sialoadenectomized animals receiving saline. After adrenaline administration plasma EGF increased by 20-fold in sham-operated but did not increase in sialoadenectomized mice. Indeed, the increase was much higher (more than 100-fold) in mice receiving exogenous EGF. The effect of adrenaline on plasma concentration of both glycerol and nonesterified fatty acids was higher as lower was plasma EGF concentration. Isolated adipocytes obtained from sham-operated or sialoadenectomized mice had identical lipolytic response to adrenaline. The lipolytic response of adipocytes to isoproterenol was decreased by addition of EGF. To study whether the interference with the in vivo lipolytic effect of adrenaline had further metabolic consequences, we measured plasma beta-hydroxybutyrate concentration in plasma. There was no difference in the response to adrenaline between sham-operated and sialoadenectomized mice in spite of the difference in plasma nonsterified fatty acid concentration. Studies in isolated hepatocytes indicated that ketogenesis run at near maximal rate in this range of substrate concentration. These results suggest that EGF in the physiological range decreases the lipolytic effect of adrenaline but does not compromise further metabolic events like the enhancement of ketogenesis.
Tebar
F
F
Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain.
Grau
M
M
Mena
M P
MP
Arnau
A
A
Soley
M
M
Ramírez
I
I
D020155:3-Hydroxybutyric Acid / Q000378:metabolism; D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D004815:Epidermal Growth Factor / Q000378:metabolism*; D004837:Epinephrine / Q000494:pharmacology*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005990:Glycerol / Q000378:metabolism; D006003:Glycogen / Q000096:biosynthesis / Q000097:blood; D007657:Ketone Bodies / Q000378:metabolism; D008066:Lipolysis / Q000187:drug effects*; D008099:Liver / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D012463:Saliva / Q000378:metabolism; D013363:Submandibular Gland / Q000378:metabolism*
D000316:Adrenergic alpha-Agonists; D005230:Fatty Acids, Nonesterified; D007657:Ketone Bodies; D004815:Epidermal Growth Factor; D006003:Glycogen; D005990:Glycerol; D020155:3-Hydroxybutyric Acid; D004837:Epinephrine